Clinical Trial

A Study of SHR-1826 Monotherapy or in Combination With Immunotherapy in the Treatment of Advanced Hepatocellular Cancer

Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The study was designed to evaluate the efficacy and safety of SHR-1826 monotherapy or in combination with immunotherapy in the treatment of advanced hepatocellular cancer patients.
Trial Details
NCT Number NCT06935175
Lead Sponsor Shanghai Zhongshan Hospital
Conditions Hepatocellular Cancer
Enrollment 53 participants
Start Date 2025-05-01
Primary Completion 2027-05-31 (estimated)
Study Completion 2028-05-31 (estimated)
Updated on ClinicalTrials.gov 2025-04-20